Egan, in his editorial of the re-analysis of the DASH-sodium data, appears to endorse universal salt reduction in the entire population, which has, according to him, a substantial foundation. 1 However, in the last paragraph, he seems to pour cold water on this conclusion and one is left uncertain as to what he is saying.
Response
The previous commentary 1 produced unintended confusion for He and MacGregor. 2 In an attempt to clarify, the DASH eating plan, 3 which contains 2400 mg Na ϩ (Ϸ100 mmol), has a high level of K ϩ , Mg ϩϩ Ca ϩϩ , fruits, vegetables, and whole grains that are associated with positive health outcomes. DASH is consonant with American Heart Association guidelines for Na ϩ , total fat, and saturated fat. Many clinical epidemiology and clinical trials confirm the benefits of this balanced nutritional program. This author supports universal implementation of the DASH eating plan with 2400 mg Na ϩ .
The DASH eating plan containing 1500 mg of Na ϩ (Ϸ60 mmol) 3 is appropriate for many hypertensives and those at high risk for hypertension. Given heterogeneous BP responses to Na ϩ restriction and potential risk to those with excessive Na ϩ losses, I do not support universal implementation of the DASH 1500 mg Na ϩ diet.
In the DASH-Sodium Study, 4 reducing Na ϩ to 100 mmol/d in a "normal" diet had a modest BP effect in volunteers (disproportionately black, middle-aged individuals with high normal BP) that are more salt sensitive than the general normotensive population. 4 Moreover, the 2400 mg Na ϩ usual diet was associated with higher BP than the 2400 mg Na ϩ DASH.
The review of longer-term studies by He and MacGregor found the net effect of reducing Na ϩ 74 mmol/d in normotensives was Ϫ2/Ϫ1 mm Hg. 5 The Intersalt study reported the mean urinary Na ϩ in the United States was Ϸ130 mmol (Ϸ3200 mg/d), which approximates daily intake. 6 Reducing this amount by 74 mmol/d leads to Na ϩ intake of Ϸ56 mmol/d (Ϸ1400 mg), well below the proposed goal of 2400 mg/d (Ϸ100 mmol). 2 Moreover, in studies with a double-blind design, the beneficial impact of salt restriction on BP is driven largely by 4 trials in which the mean age was Ͼ60 years. 5 In 2 trials with a double-blind design in individuals averaging Ͻ30 years, which is closer to the median age of the US population, the mean effect on BP is Ϫ1/ ϩ1 mm Hg. 5 The DASH-Sodium Study 4 does not provide additional compelling support for universal Na ϩ restriction to 2400 mg/d as an isolated intervention. 1 The ecological studies do not provide compelling support for universal Na ϩ restriction given nutritional, anthropometric, ethnic, and cultural differences between populations. 4 For example, a Nepalese community with Na ϩ intake of Ϸ200 mmol/d has a low prevalence of hypertension (Ϸ1.4%) and little increase of BP with age. 7 This group shares traits with other unacculaturated, low-sodium societies in Intersalt including low body mass index, limited intake of fat and processed foods, and high levels of physical activity. Including this group 7 in ecological studies might alter conclusions about sodium's effect on BP in normotensives. 6 There should be no disagreement on the principle of public health strategies to prevent hypertension. 1, 2, 5, 6 This objective merits studies on Na ϩ restriction in a representative normotensive population to generate long-term safety and efficacy data. Until that information is available, I endorse the landmark DASH Study 4 and support universal application of the DASH Eating Plan 3 with 2400 mg Na ϩ daily. 1
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